Literature DB >> 33355915

Tele-medicine versus face-to-face consultation in Endocrine Outpatients Clinic during COVID-19 outbreak: a single-center experience during the lockdown period.

F Ceccato1,2, G Voltan3, C Sabbadin3, V Camozzi3, I Merante Boschin3,4, C Mian3, V Zanotto3, D Donato5, G Bordignon5, A Capizzi5, G Carretta5, C Scaroni3.   

Abstract

CONTEXT: The COVID-19 outbreak in Italy is the major concern of Public Health in 2020: measures of containment were progressively expanded, limiting Outpatients' visit.
OBJECTIVE: We have developed and applied an emergency plan, tailored for Outpatients with endocrine diseases.
DESIGN: Cross-sectional study from March to May 2020.
SETTING: Referral University-Hospital center. PATIENTS: 1262 patients in 8 weeks.
INTERVENTIONS: The emergency plan is based upon the endocrine triage, the stay-safe procedures and the tele-Endo. During endocrine triage every patient was contacted by phone to assess health status and define if the visit will be performed face-to-face (F2F) or by tele-Medicine (tele-Endo). In case of F2F, targeted stay-safe procedures have been adopted. Tele-Endo, performed by phone and email, is dedicated to COVID-19-infected patients, to elderly or frail people, or to those with a stable disease. MAIN OUTCOME MEASURE: To assess efficacy of the emergency plan to continue the follow-up of Outpatients.
RESULTS: The number of visits cancelled after endocrine triage (9%) is lower than that cancelled independently by the patients (37%, p < 0.001); the latter reduced from 47 to 19% during the weeks of lockdown (p = 0.032). 86% of patients contacted by endocrine-triage received a clinical response (F2F and tele-Endo visits). F2F visit was offered especially to young patients; tele-Endo was applied to 63% of geriatric patients (p < 0.001), visits' outcome was similar between young and aged patients.
CONCLUSIONS: The emergency plan respects the WHO recommendations to limit viral spread and is useful to continue follow-up for outpatients with endocrine diseases.
© 2020. The Author(s).

Entities:  

Keywords:  COVID-19; Endocrine unit; Hub-spoke organization; Telemedicine

Year:  2020        PMID: 33355915      PMCID: PMC7757080          DOI: 10.1007/s40618-020-01476-2

Source DB:  PubMed          Journal:  J Endocrinol Invest        ISSN: 0391-4097            Impact factor:   4.256


  27 in total

1.  Presumed Asymptomatic Carrier Transmission of COVID-19.

Authors:  Yan Bai; Lingsheng Yao; Tao Wei; Fei Tian; Dong-Yan Jin; Lijuan Chen; Meiyun Wang
Journal:  JAMA       Date:  2020-04-14       Impact factor: 56.272

2.  Clinical spectrum of primary adrenal lymphoma: results of a multicenter cohort study.

Authors:  Fatemeh Majidi; Samuela Martino; Mustafa Kondakci; Christina Antke; Matthias Haase; Vasileios Chortis; Wiebke Arlt; Cristina L Ronchi; Martin Fassnacht; Claire Laurent; Jean-Michel Petit; Olivier Casasnovas; Mouhammed Amir Habra; Aleem Kanji; Roberto Salvatori; An Thi Nhat Ho; Ariadni Spyroglou; Felix Beuschlein; Diego Villa; Wasithep Limvorapitak; Björn Engelbrekt Wahlin; Oliver Gimm; Martina Rudelius; Matthias Schott; Ulrich Germing; Rainer Haas; Norbert Gattermann
Journal:  Eur J Endocrinol       Date:  2020-10       Impact factor: 6.664

3.  Triacylglycerol turnover in large and small rat adipocytes: effects of lipolytic stimulation, glucose, and insulin.

Authors:  J M May
Journal:  J Lipid Res       Date:  1982-03       Impact factor: 5.922

4.  Management of premature ejaculation: a clinical guideline from the Italian Society of Andrology and Sexual Medicine (SIAMS).

Authors:  A Sansone; A Aversa; G Corona; A D Fisher; A M Isidori; S La Vignera; E Limoncin; M Maggi; M Merico; E A Jannini
Journal:  J Endocrinol Invest       Date:  2020-10-30       Impact factor: 4.256

5.  Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China.

Authors:  Chaolin Huang; Yeming Wang; Xingwang Li; Lili Ren; Jianping Zhao; Yi Hu; Li Zhang; Guohui Fan; Jiuyang Xu; Xiaoying Gu; Zhenshun Cheng; Ting Yu; Jiaan Xia; Yuan Wei; Wenjuan Wu; Xuelei Xie; Wen Yin; Hui Li; Min Liu; Yan Xiao; Hong Gao; Li Guo; Jungang Xie; Guangfa Wang; Rongmeng Jiang; Zhancheng Gao; Qi Jin; Jianwei Wang; Bin Cao
Journal:  Lancet       Date:  2020-01-24       Impact factor: 79.321

6.  COVID-19 and endocrine diseases. A statement from the European Society of Endocrinology.

Authors:  M Puig-Domingo; M Marazuela; A Giustina
Journal:  Endocrine       Date:  2020-04       Impact factor: 3.633

7.  Tele-medicine versus face-to-face consultation in Endocrine Outpatients Clinic during COVID-19 outbreak: a single-center experience during the lockdown period.

Authors:  F Ceccato; G Voltan; C Sabbadin; V Camozzi; I Merante Boschin; C Mian; V Zanotto; D Donato; G Bordignon; A Capizzi; G Carretta; C Scaroni
Journal:  J Endocrinol Invest       Date:  2020-12-23       Impact factor: 4.256

8.  Endocrinology in the time of COVID-19: Management of pituitary tumours.

Authors:  Maria Fleseriu; Olaf M Dekkers; Niki Karavitaki
Journal:  Eur J Endocrinol       Date:  2020-07       Impact factor: 6.664

9.  COVID-19 infection: the perspectives on immune responses.

Authors:  Yufang Shi; Ying Wang; Changshun Shao; Jianan Huang; Jianhe Gan; Xiaoping Huang; Enrico Bucci; Mauro Piacentini; Giuseppe Ippolito; Gerry Melino
Journal:  Cell Death Differ       Date:  2020-03-23       Impact factor: 15.828

10.  ENDOCRINOLOGY IN THE TIME OF COVID-19: Management of Cushing's syndrome.

Authors:  John Newell-Price; Lynnette K Nieman; Martin Reincke; Antoine Tabarin
Journal:  Eur J Endocrinol       Date:  2020-07       Impact factor: 6.558

View more
  7 in total

1.  COVID-19 lockdown negatively impacted on adherence to denosumab therapy: incidence of non-traumatic fractures and role of telemedicine.

Authors:  S De Vincentis; D Domenici; A Ansaloni; G Boselli; G D'Angelo; A Russo; E Taliani; V Rochira; M Simoni; B Madeo
Journal:  J Endocrinol Invest       Date:  2022-05-19       Impact factor: 5.467

2.  Tele-medicine versus face-to-face consultation in Endocrine Outpatients Clinic during COVID-19 outbreak: a single-center experience during the lockdown period.

Authors:  F Ceccato; G Voltan; C Sabbadin; V Camozzi; I Merante Boschin; C Mian; V Zanotto; D Donato; G Bordignon; A Capizzi; G Carretta; C Scaroni
Journal:  J Endocrinol Invest       Date:  2020-12-23       Impact factor: 4.256

Review 3.  Frequently Asked Questions in Patients With Adrenal Insufficiency in the Time of COVID-19.

Authors:  Chiara Sabbadin; Corrado Betterle; Carla Scaroni; Filippo Ceccato
Journal:  Front Endocrinol (Lausanne)       Date:  2021-12-24       Impact factor: 5.555

4.  The Overall Survival and Progression-Free Survival in Patients with Advanced Adrenocortical Cancer Is Increased after the Multidisciplinary Team Evaluation.

Authors:  Irene Tizianel; Mario Caccese; Francesca Torresan; Giuseppe Lombardi; Laura Evangelista; Filippo Crimì; Matteo Sepulcri; Maurizio Iacobone; Marta Padovan; Francesca Galuppini; Vittorina Zagonel; Carla Scaroni; Filippo Ceccato
Journal:  Cancers (Basel)       Date:  2022-08-12       Impact factor: 6.575

5.  Systemic steroids in patients with COVID-19: pros and contras, an endocrinological point of view.

Authors:  A M Berton; N Prencipe; R Giordano; E Ghigo; S Grottoli
Journal:  J Endocrinol Invest       Date:  2020-06-08       Impact factor: 4.256

Review 6.  A Narrative Review of the Launch and the Deployment of Telemedicine in Italy during the COVID-19 Pandemic.

Authors:  Daniele Giansanti; Giovanni Morone; Alice Loreti; Marco Germanotta; Irene Aprile
Journal:  Healthcare (Basel)       Date:  2022-02-23

7.  Health care access of thyroid disease patients in Serbia during the COVID-19 pandemic.

Authors:  M Žarković; P Perros; J Ćirić; B Beleslin; M Stojanović; M Stojković; M Miletić; T Janić
Journal:  J Endocrinol Invest       Date:  2022-03-24       Impact factor: 5.467

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.